The goal was never to use AI everywhere. It was to get patients to therapy faster, execute more accurately, and support the people doing this work in making smarter decisions. Access leaders who ...

Biopharma logged ~36 >$1B EV deals through mid-2026 totaling ~$140B, with total M&A estimated at $160B–$165B, implying an annualized run rate exceeding $300B. Patent-expiry exposure remains a primary ...

A compressed 150-day period saw policy and market shifts that outpaced typical formulary-driven timelines and catalyzed manufacturer adoption of direct-to-patient infrastructure. Rising prescription ...

Pharmaceutical Commerce continues its H1 Review/H2 Outlook series, checking in with industry experts on the forecasts they made earlier this year. This installment features Chip Parkinson, CEO of ...

Four pharma commerce voices check back in at the midpoint of 2026 to see how their dealmaking, patient access and commercialization predictions have held up. As the pharmaceutical industry crosses the ...

Pairing packaging hardware with AI software enables a unified offering spanning physical protection, live sensor telemetry, automated deviations workflows, and audit-ready reporting for GDP-aligned ...

Geopolitical supply chain mapping identifies hidden dependencies across corridors, ports, airports, customs gateways, and carriers that can undermine continuity despite apparent supplier ...

Persistent shortages increasingly reflect underinvestment and product exits, with 95% of 2025 shortages carried over and average duration exceeding five years, indicating a hardened, structural ...

Amy Niles of the Patient Advocate Foundation on the Medicare Part D cap, Medicaid, ACA exchanges and rural hospital access in late 2026. Pharmaceutical Commerce continues its H1 Review/H2 Outlook ...

Shawn Seamans, Chief Commercial Officer, CoverMyMeds | Authors | Pharmaceutical Commerce connects biopharma executives to insights on business processes, technologies, and strategies for taking ...